Moxotens (Moxonidine)

Moxonidine, the active ingredient in Moxotens, is an Imidazoline I1 receptor agonist presented as an oral tablet for oral use. It is used to treat hypertension in adult patients. GNH USA supplies Moxotens as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Moxonidine is indicated for the management of elevated blood pressure within the antihypertensive drug class.

Hypertension: helps lower systolic and diastolic blood pressure by reducing sympathetic nervous system activity.

Moxonidine may cause a range of adverse reactions, most of which are mild to moderate in severity.

Common Side Effects: - Dry mouth: sensation of reduced salivation. - Fatigue: feeling of tiredness or lack of energy. - Dizziness: light‑headedness, especially when standing quickly. - Headache: mild to moderate cranial pain. - Nausea: feeling of stomach upset. - Peripheral edema: mild swelling of the lower limbs.

Serious or Rare Side Effects: - Severe hypotension: markedly low blood pressure requiring medical attention. - Bradycardia: abnormally slow heart rate. - Hepatic dysfunction: abnormal liver enzyme elevations. - Allergic reactions: rash, itching, or swelling. - Syncope: temporary loss of consciousness. - Renal impairment: worsening kidney function.

Before initiating therapy, consider the following safety measures.

Pregnancy: avoid use unless the potential benefit justifies the risk, as safety data are limited. Breastfeeding: discontinue if adverse effects are observed in the infant. Renal impairment: dose may need adjustment in patients with reduced kidney function. Hepatic disease: monitor liver function tests during treatment. Concomitant antihypertensives: watch for additive blood‑pressure lowering effects. Store at ambient temperature: keep below 25 °C, retain in original packaging, and protect from moisture.

Moxonidine can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Combined use with other central antihypertensives (e.g., clonidine) may cause excessive hypotension. - Potassium‑sparing diuretics: risk of hyperkalaemia. - Strong CYP2D6 inhibitors: may increase plasma concentrations.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may blunt antihypertensive effect. - Beta‑blockers: additive heart‑rate reduction. - Diuretics: monitor electrolytes and blood pressure. - Alcohol: may enhance dizziness and hypotension.